Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2125 | 2017 |
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 … T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ... The Lancet 391 (10122), 748-757, 2018 | 1388 | 2018 |
Erdafitinib in locally advanced or metastatic urothelial carcinoma Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ... New England Journal of Medicine 381 (4), 338-348, 2019 | 1157 | 2019 |
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 725 | 2019 |
Enfortumab vedotin in previously treated advanced urothelial carcinoma T Powles, JE Rosenberg, GP Sonpavde, Y Loriot, I Durán, JL Lee, ... New England Journal of Medicine 384 (12), 1125-1135, 2021 | 706 | 2021 |
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, ... Nature medicine 25 (11), 1706-1714, 2019 | 496 | 2019 |
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 407 | 2020 |
Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 368 | 2020 |
Biomarkers of response to PD-1/PD-L1 inhibition SM Vareki, C Garrigós, I Duran Critical reviews in oncology/hematology 116, 116-124, 2017 | 326 | 2017 |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Annals of Oncology 28 (7), 1508-1516, 2017 | 273 | 2017 |
Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis FE Vera-Badillo, AJ Templeton, I Duran, A Ocana, P de Gouveia, P Aneja, ... European urology 67 (4), 740-749, 2015 | 208 | 2015 |
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus I Duran, LL Siu, AM Oza, TB Chung, J Sturgeon, CA Townsley, GR Pond, ... European Journal of Cancer 42 (12), 1875-1880, 2006 | 196 | 2006 |
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection R Garcia-Carbonero, R Salazar, I Duran, I Osman-Garcia, L Paz-Ares, ... Journal for immunotherapy of cancer 5, 1-13, 2017 | 157 | 2017 |
Systemic treatment of renal cell cancer: A comprehensive review A Sánchez-Gastaldo, E Kempf, AG Del Alba, I Duran Cancer treatment reviews 60, 77-89, 2017 | 152 | 2017 |
Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia A Jimeno, A García‐Velasco, O del Val, E González‐Billalabeitia, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 148 | 2004 |
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) E Grande, J Capdevila, D Castellano, A Teulé, I Durán, J Fuster, I Sevilla, ... Annals of oncology 26 (9), 1987-1993, 2015 | 140 | 2015 |
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors LL Siu, R Pili, I Duran, WA Messersmith, EX Chen, R Sullivan, M MacLean, ... Journal of clinical oncology 26 (12), 1940-1947, 2008 | 140 | 2008 |
Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the … CN Sternberg, Y Loriot, N James, E Choy, D Castellano, F Lopez-Rios, ... European urology 76 (1), 73-81, 2019 | 135 | 2019 |
Chromophobe renal cell carcinoma: a review of an uncommon entity FE Vera‐Badillo, E Conde, I Duran International Journal of Urology 19 (10), 894-900, 2012 | 133 | 2012 |
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 127 | 2022 |